<?xml version="1.0" encoding="UTF-8"?>
<p id="p0105">Finally, EUAs may be issued for antiviral drug products as well as for anti-inflammatory drug/biologic medicinal products as they are identified and directed toward specific patient populations, possibly as early as Phase II for new products and possibly any time after a repurposed product is considered potentially effective. EUAs may also play a role in making vaccines available. We have also seen EUA withdrawals in the cases of chloroquine and hydroxychloroquine after the FDA determined that they were “unlikely to be effective in treating COVID-19 for the authorized uses in the EUA”.
 <xref rid="bib33" ref-type="bibr">
  <sup>33</sup>
 </xref>
</p>
